ENDONOVO THERAPEUTICS, INC. (OTCMKTS:ENDV) Files An 8-K Material Modification to Rights of Security HoldersItem 3.03
On September 18, 2018, the Registrant filed a certificate of amendment to its certificate of incorporation to increase the number of shares of common stock which it may issue from 500,000,000 to 2,500,000,000. The amendment was approved by over 60% of the voting power of the Registrant.
| Item 9.01 | Financial Statements and Exhibits. |
| (a) | Financial Statements -None |
| (b) | Exhibits |
| 3.1 | Certificate of Amendment |
ENDONOVO THERAPEUTICS, INC. Exhibit…To view the full exhibit click here
About ENDONOVO THERAPEUTICS, INC. (OTCMKTS:ENDV)
Endonovo Therapeutics, Inc., formerly Hanover Portfolio Acquisitions, Inc., is a biotechnology company developing a bioelectronic approach to regenerative medicine. The Company operates through two segments: intellectual property licensing and commercialization, and biomedical research and development, which includes development of its square wave form device. Its Immunotronics platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation and cell death. Its Cytotronics platform is being developed to create biologically potent cell therapies. It is using this technology to create a therapy for the treatment of Graft-Versus-Host Disease (GvHD), a rare complication following allogeneic tissue transplants. Its Cytotronics platform provides for a method of expanding and manipulating cells using simulated microgravity and Time-Varying Electromagnetic Fields for tissue engineering and cell therapies.
